The nonerosive reflux disease-gastroesophageal reflux disease controversy

Current Opinion in Gastroenterology

Volumn 24, Issue 4, 2008, Pages 509-515

  Winter, Jack W ^a   Heading, Robert C ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Functional heartburn; Gastroesophageal reflux disease; Nonerosive reflux disease

Indexed keywords

PROTON PUMP INHIBITOR;

ACUPUNCTURE; ADENOCARCINOMA; ANXIETY; ASTHMA; BARRETT ESOPHAGUS; BLEEDING; COUGHING; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; ENDOSCOPY; ESOPHAGUS FUNCTION DISORDER; ESOPHAGUS MOTILITY; ESOPHAGUS STRICTURE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HELICOBACTER INFECTION; HEREDITY; HIATUS HERNIA; HUMAN; INCIDENCE; IRRITABLE COLON; NARROW BAND IMAGING; NONCARDIAC CHEST PAIN; NONEROSIVE REFLUX DISEASE; OBESITY; PATHOPHYSIOLOGY; PH; PHYSICAL ACTIVITY; PREVALENCE; REFLUX ESOPHAGITIS; REVIEW; SMOKING; SOCIAL CLASS; STOMACH FUNCTION DISORDER;

ALGORITHMS; ESOPHAGUS; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; MUCOUS MEMBRANE; PROTON PUMP INHIBITORS;

EID: 66349124792     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283025c57     Document Type: Review

References (51)

1. Vakil N, van Zanten SV, Kahrilas P, et al.The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101:1900-1920.
2. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management: the Genval workshop report. Gut 1999; 44:S1-S16.
3. Fennerty MB. Extraesophageal gastroesophageal reflux disease: presentations and approach to treatment. Gastroenterol Clin North Am 1999; 28:861-873; vi.
4. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease: current concepts and dilemmas. Am J Gastroenterol 2001; 96:303-314.
5. Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol Suppl 1993; 199:18-21.
6. Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease: an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003; 18:767-776.
7. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease: where next? Aliment Pharmacol Ther 2005; 22:79-94.
8. Galmiche JP, Clouse RE, Balint A, et al. Functional esophageal disorders. Gastroenterology 2006; 130:1459-1465.
9. Clouse RE, Richter JE, Heading RC, et al. Functional esophageal disorders. Gut 1999; 45 (Suppl 2):II31-II36.
10. Pace F, Pallotta S, Vakil N. Gastroesophageal reflux disease is a progressive disease. Dig Liver Dis 2007; 39:409-414.
11. Fass R, Ofman JJ. Gastroesophageal reflux disease: should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97:1901 -1909.
12. Quigley EMM. NERD, GERD, and beyond: a consideration of the expanding spectrum of gastroesophageal reflux disease. J Clin Gastroenterol 2007; 41:S175-S180.
13. Locke GR 3rd, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112:1448-1456.
14. Ruigomez A, Wallander MA, Johansson S, et al. Natural history of gastroesophageal reflux disease diagnosed in UK general practice. Aliment Pharmacol Ther 2004; 20:751 -760.
15. Kotzan J, Wade W, Yu HH. Assessing NSAID prescription use as a predisposing factor for gastroesophageal reflux disease in a Medicaid population. Pharm Res 2001; 18:1367-1372.
16. El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol 2007; 5:17-26.
17. Ronkainen J, Aro P, StorskrubbT, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 2005; 40:275-285.
18. MishimaI, Adachi K, ArimaN, et al. Prevalence of endoscopically negative and positive gastroesophageal reflux disease in the Japanese. Scand J Gastroenterol 2005; 40:1005-1009.
19. Zheng Z, Nordenstedt H, Pedersen NL, et al. Lifestyle factors and risk for symptomatic gastroesophageal reflux in monozygotic twins. Gastroenterology 2007; 132:87-95.
20. Jansson C, Nordenstedt H, Wallander MA, et al. Severe gastro-oesophageal reflux symptoms in relation to anxiety, depression and coping in a population-based study. Aliment Pharmacol Ther 2007; 26:683-691.
21. Jansson C, Nordenstedt H, Johansson S, et al.Relation between gastro- esophageal reflux symptoms and socioeconomic factors: a populationbased study (the HUNT Study). Clin Gastroenterol Hepatol 2007; 5: 1029-1034.
22. Pimentel M, Rossi F, Chow EJ, et al. Increased prevalence of irritable bowel syndrome in patients with gastroesophageal reflux. J Clin Gastroenterol 2002; 34:221-224.
23. Nastaskin I, Mehdikhani E, Conklin J, et al. Studying the overlap between IBS and GERD: a systematic review of the literature. Dig DisSci 2006; 51:2113-2120.
24. Jung HK, Halder S, McNally M, et al. Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. Aliment Pharmacol Ther 2007; 26:453-461.
25. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007;41:131-137.
26. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998; 10:119-124.
27. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis: a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13:907-914.
28. Lee YC, Wang HP, Chiu HM, et al. Comparative analysis between psychological and endoscopic profiles in patients with gastroesophageal reflux disease: a prospective study based on screening endoscopy. J Gastroenterol Hepatol 2006; 21:798-804.
29. Wu JC, Cheung CM, Wong VW, Sung JJ. Distinct clinical characteristics between patients with nonerosive reflux disease and those with reflux esophagitis. Clin Gastroenterol Hepatol 2007; 5:690-695.
30. Fass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98:S2-S7.
31. Cameron AJ. Barrett's esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol 1999; 94:2054-2059.
32. HoKY, Kang JY. Reflux esophagitis patients in Singapore have motor and acid exposure abnormalities similar to patients in the Western hemisphere. Am J Gastroenterol 1999; 94:1186-1191.
33. Martinez SD, Malagon IB, Garewal HS, et al. Nonerosive reflux disease (NERD): acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17:537-545.
34. Shapiro M, Green C, Faybush EM, et al. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups. Aliment Pharmacol Ther 2006; 23:321 -329.
35. Frazzoni M, Manno M, De Micheli E, Savarino V. Pathophysiological characteristics of the various forms of gastro-oesophageal reflux disease: spectrum disease or distinct phenotypic presentations? Dig Liver Dis 2006; 38:643-648.
36. Emerenziani S, Cicala M, Zhang X, et al. Effect of oesophagitis on proximal extent of gastro-oesophageal reflux. Neurogastroenterol Motil 2007; 19: 459-464.
37. Dickman R, Bautista JM, Wong WM, et al. Comparison of esophageal acid exposure distribution along the esophagus among the different gastroesophageal reflux disease (GERD) groups. Am J Gastroenterol 2006; 101: 2463-2469.
38. Bredenoord AJ, Weusten BL, Curvers WL, et al. Determinants of perception of heartburn and regurgitation. Gut 2006; 55:313-318.
39. Zerbib F, Duriez A, Roman S, et al. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut 2008; 57:156-160.
40. van Malenstein H, Farre R, Sifrim D. Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. Am J Gastroenterol 2007; 12 December [Epub ahead of print].
41. Farre R, De Vos R, Geboes K, et al. Critical role of stress in increased oesophageal mucosa permeability and dilated intercellular spaces. Gut 2007; 56:1191 -1197.
42. Sharma P, Wani S, Bansal A, et al. A feasibility trial of narrow band imaging endoscopy in patients with gastroesophageal reflux disease. Gastroenterology 2007; 133:454-464.
43. Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006; 101:1956-1963.
44. Bredenoord AJ, Weusten BL, Timmer R, et al. Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy. Am J Gastroenterol 2006; 101:453-459.
45. Labenz J, Nocon M, Lind T, et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol 2006; 101:2457-2462.
46. Quigley EM. Getting categorical on GERD. Am J Gastroenterol 2007; 102:1130; author reply 1131.
47. Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2:656-664.
48. Armstrong D, Talley NJ, Lauritsen K, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004; 20:413-421.
49. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32:974-979.
50. Pandolfino JE, Shah N. A new confusing model of GERD: a spectrum of phenotypic progression. Dig Liver Dis 2006; 38:648-651.
51. Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther 2007; 26:1333-1344.